32+ results for “Duchenne muscular dystrophy”
The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The participants who are randomized to the placebo arm will have an opportunity for treatment with gene transfer therapy at the beginning of the second year.
Lead muscle-tropic AAV capsid from M-CREATE directed evolution with 100-fold greater skeletal and cardiac muscle transduction than AAV9. Cross-species validated in mouse, pig, and non-human primate with substantially reduced liver off-target uptake. Primary delivery vector for Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and cardiomyopathy gene therapy.
Chimeric serotype combining AAV2 and AAV5 capsid sequences for enhanced muscle transduction with improved tissue distribution.
Natural serotype with exceptionally strong skeletal muscle, cardiac muscle, and lung tropism. Clinically relevant for muscle and airway diseases.
Natural AAV serotype with strong skeletal and cardiac muscle tropism. One of the earliest discovered and most clinically relevant serotypes for muscle-directed gene therapy.
A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation
Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery
A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector